Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $55,252 | $682 | $0 | $0 |
| % Growth | 8,001.5% | – | – | – |
| Cost of Goods Sold | $7,973 | $167 | $620 | $521 |
| Gross Profit | $47,279 | $515 | -$620 | -$521 |
| % Margin | 85.6% | 75.5% | – | – |
| R&D Expenses | $34,082 | $49,899 | $71,441 | $72,338 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $290,664 | $117,928 | $100,379 | $62,221 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $324,746 | $167,827 | $171,820 | $134,559 |
| Operating Income | -$277,467 | -$167,312 | -$172,440 | -$135,080 |
| % Margin | -502.2% | -24,532.6% | – | – |
| Other Income/Exp. Net | -$56,859 | -$34,280 | -$25,283 | -$8,803 |
| Pre-Tax Income | -$334,326 | -$201,592 | -$197,723 | -$143,883 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$334,326 | -$201,592 | -$197,723 | -$143,883 |
| % Margin | -605.1% | -29,558.9% | – | – |
| EPS | -5.29 | -3.93 | -5.7 | -4 |
| % Growth | -34.6% | 31.1% | -42.5% | – |
| EPS Diluted | -5.29 | -3.93 | -5.7 | -4 |
| Weighted Avg Shares Out | 63,176 | 51,289 | 39,118 | 37,003 |
| Weighted Avg Shares Out Dil | 63,176 | 51,289 | 39,118 | 37,003 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,158 | $7,876 | $2,132 | $41 |
| Interest Expense | $72,009 | $41,968 | $27,305 | $6,788 |
| Depreciation & Amortization | $795 | $575 | $620 | $521 |
| EBITDA | -$261,522 | -$159,049 | -$169,798 | -$136,574 |
| % Margin | -473.3% | -23,321% | – | – |